Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 13/20 | 0.53 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 11/20 | 0.46 |
| ▸ | CDC25B | P30305 | 11/20 | 0.46 |
| ▸ | MAOB | P27338 | 6/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 7/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6389087 | 0.82 | PTPN1 (0.49) | PTPN1PARP15PARP10PTPN2CDC25B | |
| Netoglitazone SCHEMBL29355960 | 0.80 | FFAR1 (0.55) | PTPN1PARP15PARP10PTPN2CDC25B | |
| Netoglitazone SCHEMBL29355957 | 0.80 | FFAR1 (0.55) | PTPN1PARP15PARP10PTPN2CDC25B | |
| Netoglitazone SCHEMBL29434827 | 0.80 | FFAR1 (0.55) | PTPN1PARP15PARP10PTPN2CDC25B | |
| Netoglitazone SCHEMBL20125595 | 0.80 | FFAR1 (0.55) | PTPN1PARP15PARP10PTPN2CDC25B | |
| Netoglitazone SCHEMBL142658 | 0.80 | FFAR1 (0.55) | PTPN1PARP15PARP10PTPN2CDC25B | |
| Netoglitazone SCHEMBL29361540 | 0.80 | FFAR1 (0.55) | PTPN1PARP15PARP10PTPN2CDC25B | |
| Netoglitazone SCHEMBL20125596 | 0.80 | FFAR1 (0.55) | PTPN1PARP15PARP10PTPN2CDC25B | |
| Netoglitazone SCHEMBL8877880 | 0.79 | FFAR1 (0.54) | PTPN1PARP15PARP10PTPN2CDC25B | |
| SCHEMBL7514724 | 0.76 | PTPN1 (0.45) | PTPN1PARP15PARP10PTPN2CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060149075-A1 | Crystals of 5-[{6-(2-fluorobenzyl)oxy-2-naphthyl}methyl]-2,4-thiazolidinedione | OE TAKAYUKI | 2006-07-06 | — | — | US | claimed |
| EP-1131310-B1 | CHRYSTALS OF 5- 6-(2-FLUOROBENZYL)OXY-2-NAPHTHYL METHYL]-2,4-THIAZOLIDINEDIONE | MITSUBISHI CHEM CORP (JP) | 2006-01-11 | — | — | EP | claimed |
| US-20040106649-A1 | Agent for improving acidosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-03 | — | — | US | claimed |
| US-6677363-B1 | ADMINISTERING PIOGLITAZONE OR SALT, OXIME INSULIN SENSITIZER, FK-614, KRP-297, AND 5-((6-(2-FLUOROBENZYLOXY)-2-NAPHTHYL)METHYL)-2,4-THIAZOLIDINEDIONE TO TREAT DIABETES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-01-13 | — | — | US | claimed |
| US-20030158241-A1 | Crystals of 5-[{6-(2-fluorobenzyl)oxy-2-naphthyl}methyl]-2,4-thiazolidinedione | OE TAKAYUKI (JP) | 2003-08-21 | — | — | US | claimed |
| US-6541493-B1 | Type A, B, C and D crystals of said compound; excellent in stability, and has advantages in handling, storage, and pharmaceutical preparation. | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-04-01 | — | — | US | claimed |
| US-6399639-B1 | ADMINISTERING A 2,4-THIADIAZOLIDINEDIONE COMPOUND | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-06-04 | — | — | US | claimed |
| EP-1131310-A1 | CHRYSTALS OF 5- 6-(2-FLUOROBENZYL)OXY-2-NAPHTHYL METHYL]-2,4-THIAZOLIDINEDIONE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2001-09-12 | — | — | EP | claimed |
| WO-2000031055-A1 | CHRYSTALS OF 5-[{6-(2-FLUOROBENZYL)OXY-2-NAPHTHYL}METHYL]-2,4-THIAZOLIDINEDIONE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2000-06-02 | — | — | WO | claimed |
| US-20230210808-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| CN-109715637-B | Glucokinase activators and methods of use thereof | 百时美施贵宝公司 | 2022-04-05 | — | — | CN | disclosed |
| US-11007162-B2 | Methods of reducing small, dense LDL particles | CYMABAY THERAPEUTICS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10604541-B2 | Glucokinase activators and methods of using same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190298672-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | CYMABAY THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | US | disclosed |
| WO-2000061127-A2 | USE OF INSULIN SENSITISERS FOR IMPROVING KETOSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-19 | — | — | WO | disclosed |
| US-6087384-A | TREATING PROPHYLAXIS AND TREATMENT OF A DISEASE ASSOCIATE WITH DEATH OF CELLS CAUSED BY VIRAL DISEASES, MYELODYSPLASIS, NEURODEGENERATIVE, ISCHEMIC AND HEPATIC DISEASES WITH A COMPOUND HAVING AN INSULIN SENSITIVITY ENHANCING ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
| WO-2000031055-A1 | CHRYSTALS OF 5-[{6-(2-FLUOROBENZYL)OXY-2-NAPHTHYL}METHYL]-2,4-THIAZOLIDINEDIONE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000031055-A1 | CHRYSTALS OF 5-[{6-(2-FLUOROBENZYL)OXY-2-NAPHTHYL}METHYL]-2,4-THIAZOLIDINEDIONE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000031055-A1 | CHRYSTALS OF 5-[{6-(2-FLUOROBENZYL)OXY-2-NAPHTHYL}METHYL]-2,4-THIAZOLIDINEDIONE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000000195-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190298672-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | LDLR, APOB, HDLBP | PTPN1 2098/4885PARP15 2154/4885PARP10 2644/4885 |
| US-10604541-B2 | Glucokinase activators and methods of using same | GCK, GCKR, GALK1 | PTPN1 2880/4885PARP15 3629/4885PARP10 4058/4885 |
| US-20230210808-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PTPN1 346/4885PARP15 4038/4885PARP10 4465/4885 |
| US-20060149075-A1 | Crystals of 5-[{6-(2-fluorobenzyl)oxy-2-naphthyl}methyl]-2,4-thiazolidinedione | CYP4B1, NT5C, NPC1L1 | PTPN1 531/4885PARP15 2753/4885PARP10 4511/4885 |
| US-20040106649-A1 | Agent for improving acidosis | GPR119, SLC2A8, SLC2A1 | PTPN1 3972/4885PARP15 4236/4885PARP10 3861/4885 |
| US-11007162-B2 | Methods of reducing small, dense LDL particles | LDLR, APOB, HDLBP | PTPN1 2098/4885PARP15 2154/4885PARP10 2644/4885 |
| US-20030158241-A1 | Crystals of 5-[{6-(2-fluorobenzyl)oxy-2-naphthyl}methyl]-2,4-thiazolidinedione | CYP4B1, NT5C, SLCO2B1 | PTPN1 1205/4885PARP15 1904/4885PARP10 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.